Merck Stock News

When blue-chip bargains are raining from the sky, it's time to bend it like Buffett and buy. Check out the 11 highest quality Ultra SWAN stocks in 11 sectors.

This drugmaker has a bright future.

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

Sector ETF report for PJP

Sector ETF report for IHE

Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.

Merck & Co Inc (NYSE: MRK ) announced data from Phase 3 KEYNOTE-716 trial of Keytruda (pembrolizumab) as adjuvant treatment for patients with resected stage IIB and IIC melanoma. The trial has met its key secondary endpoint of distant metastasis-free survival (DMFS) at a prespecified interim analysis. In the trial, adjuvant … Full story available on Benzinga.com

Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.

Updating results from its KEYNOTE-716 trial, Merck (MRK) said that its blockbuster anti-PD-1 therapy, Keytruda met the key secondary endpoint of the trial among patients with resected…

NEW YORK , March 6, 2022 /PRNewswire-PRWeb/ -- The Conference Forum is pleased to announce that the 9th annual Patients as Partners® in Clinical Research conference is back in-person on April 28-29, 2022 at the Sheraton Philadelphia Downtown hotel, Philadelphia, PA. Patients as Partners® US is the first conference in the US guided by patients with Pharma R&D executives and FDA to demonstrate how patient involvement gets implemented throughout the medicines development cycle in order to drive greater efficiencies in getting therapeutics to patients faster. "Patients as Partners demonstrates how to truly work with patients and it remains the all time best forum to hear about the latest and greatest initiatives and innovations in patient engagement.," said Dr Luther Clark , Deputy Chief Patient Officer & Global Director, Scientific, Medical and Patient Perspective, Merck and Co-chair of the Summit. "There are great opportunities to learn more about what it means to put patients first and why the importance of involving patients early in medicines development is greater now than ever before." The event is co-chaired by Rolf Benirschke , patient advocate and former NFL player; Luther Clark , MD, Deputy Chief Patient Officer & Global Director, Scientific, Medical and Patient Perspective, Merck; Katherine Capperella , VP, Global Patient …

The reasons to buy Merck's stock are more than just its market-beating dividend yield.

The reasons to buy Merck''s stock are more than just its market-beating dividend yield.

It's always a good idea to keep your wish list ready by separating the wheat from the chaff. What are 5 safe and cheap dividend stocks to invest? Find out.

Merck (MRK) closed at $77.83 in the latest trading session, marking a +0.88% move from the prior day.